Synthesis, In silico Studies, and Biological Evaluation of Benzotriazole-Fused Thiazole-containing Schiff Bases as Potential Therapeutic Agents for Microbial Infections in Respiratory Disorders.

INTRODUCTION

Respiratory disorders pose a significant global health challenge, often worsened by bacterial and fungal infections. Schiff bases have gained attention for their antimicrobial properties, making them promising candidates for drug development and potential patent applications. This study explores the synthesis, computational analysis, and biological evaluation of thiazole-containing Schiff bases as therapeutic agents.

MATERIALS AND

METHODS

A series of Schiff base compounds (9a-9h) was synthesized and characterized using spectroscopy and chromatography techniques. Computational studies, including molecular docking, ADME profiling, and physicochemical analyses, were performed to compare them with standard antimicrobial drugs (Amoxicillin and Fluconazole). Antimicrobial efficacy was assessed against Escherichia coli, Bacillus subtilis, and Candida albicans using the broth microdilution method in 96-well plates to determine minimum inhibitory concentrations (MICs).

RESULTS

Among the synthesized compounds, 9c exhibited potent antimicrobial activity, with MIC values of 12.76 μg/mL against B. subtilis and 25.52 μg/mL against C. albicans. Compound 9g showed strong activity against E. coli, with an MIC value of 12.76 μg/mL. Spectroscopic and computational analyses validated their structural stability and bioactive potential.

DISCUSSION: The observed antimicrobial activity highlights the therapeutic promise of thiazole-containing Schiff bases in combating microbial infections associated with respiratory diseases. Their potency, compared to standard antibiotics and antifungal agents, underscores the need for further pharmacological evaluation, optimization, and patent consideration.

CONCLUSION

Thiazole-containing Schiff bases demonstrate significant antimicrobial potential, particularly against respiratory-related pathogens. These findings warrant further investigation into their pharmacological properties to develop new treatment options for microbial infections in respiratory disorders, with scope for patentable innovations.